Loading data for SDGR — first visit, this takes a few seconds.

アラート

Schrödinger Inc. (SDGR)

NasdaqGS: SDGR · リアルタイム株価 · USD

19.57

-0.42 (-2.10%)

終値時点： Aug 26, 2026, 3:59 PM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

-2.10% (1D)

買気配	18.1
時価総額	1.49B
売上高（TTM）	259.04M
純利益（TTM）	-54.34M
	1.66
	-0.73
	n/a
	-14.8
PBR（TTM）	4.43
PSR（TTM）	5.77
決算発表日	Nov 4, 2026

売気配	21.25
出来高	378,298
平均出来高（20日）	1,259,979
始値	19.89
前日終値	19.99
当日レンジ	19.30 - 19.98
52週レンジ	10.95 - 23.02
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

SDGRについて

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials s...

[続きを読む]

業種 Health Information Services

セクター Healthcare

IPO日 Feb 6, 2020

従業員数 850

上場取引所 NasdaqGS

ティッカー SDGR

ウェブサイト https://www.schrodinger.com

企業情報の全文

業績

2025年のSchrödingerの売上高は255.87Mで、前年の207.54Mから23.29%の増加でした。利益は-103.27Mで、-44.81%の減少でした。

財務諸表

決算サプライズ

SchrödingerはAug 5, 2026に四半期決算を発表しました：

売上高は $58.89M で、予想を下回りました $0, うち 7.54% の前年比増加にあたります.
EPSは -0.42 で、予想を上回りました 0.25, うち 35.38% の前年比増加にあたります.

次回決算発表

Schrödinger Inc.の決算発表予定日は Nov 4, 2026, 取引時間中の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

1週間前 · Zacks

The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci

AI is reshaping drug discovery, with Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci advancing computational platforms and pipelines.

1週間前 · Zacks

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.

2週間前 · 24/7 Wall St.

The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)

Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one has climbed...

3週間前 · Simply Wall St.

Schrödinger (SDGR) Is Up 8.5% After AI Co‑Scientist Deal With BMS And Q2 Profitability Shift – Has The Bull Case Changed?

In the past few days, Schrödinger, Inc. reported second-quarter 2026 results showing revenue of US$58.89 million and a shift to a US$5.98 million net profit, while also expanding its long-running coll...

3週間前 · GuruFocus.com

Schrodinger Inc (SDGR) (Q2 2026) Earnings Call Highlights: ACV Surges 27% on Bunsen Launch and ...

Schrodinger Inc (SDGR) reports robust Q2 2026 with record ACV growth, strategic AI advancements, and raised full-year drug discovery guidance despite margin pressures from hosted transition.

2ページ中1ページ

Schrödinger Inc. (SDGR)